Moderna's Breakthrough: Combined COVID and Flu Vaccine Shows Promising Results

Moderna announced promising results for its phase 3 clinical trial of a combined COVID and flu vaccine. The trial found the vaccine elicited a higher immune response compared to separate shots, and was well-tolerated. This could boost vaccination rates, especially in low-resource areas and vulnerable populations.

In a significant advancement, Moderna announced positive outcomes from its phase 3 clinical trial of a combined COVID-19 and influenza vaccine earlier this week.

The trial, which included around 8,000 participants aged 50 and above, revealed that the combined vaccine elicited a stronger immune response against both COVID-19 and three strains of influenza compared to separate shots.

From a safety standpoint, the vaccine was well tolerated with common side effects like muscle aches and fatigue. Though the results are yet to be peer-reviewed, this two-in-one vaccine could notably enhance public health efforts and vaccination rates.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)